Inhaled mRNA therapy for cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests an inhaled mRNA therapy (BMD003) for adults with cystic fibrosis. It aims to see if the treatment is safe and can help improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of cystic fibrosis
- Your cystic fibrosis should be stable, with no recent serious infections or changes in medications in the last month
- Your lung function (FEV1) must be at least 40% of normal
- You must be at least 18 years old and weigh at least 40 kg
- You must have quit smoking for at least 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
This study tests a new type of MRI scan that uses either special gas (xenon) or regular MRI to take detailed pictures of the lungs in people with cystic fibrosis. The goal is to see how well these scans can track lung health over time, without using X-ray radiation.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This study looks at correcting “stop” mistakes (nonsense mutations) in the CFTR gene, which can cause cystic fibrosis. If your CFTR test shows the exact type of mutation the study needs, you may be able to take part.
Hear when a new Gene Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.